Chargement de votre page…
World Journal of Pharmaceutical Research
Par Pooja T.1*, Samiya Eram1, Sindhu L.1, C. M. Chandana1, Abhishek C. Pasarad2.
Contenu en anglais
This study explores the neuroprotective potential of sitagliptin, an anti-diabetic drug, in managing Alzheimer's disease (AD) symptoms in a streptozotocin (STZ)-induced rat model.
Ward réunit ces articles dans la même app que vos cartes et vos questions. Un seul compte gratuit pour Ward, Suture, Osler et Prognia.
This research aimed to assess whether sitagliptin could improve cognitive function and reduce anxiety by modulating acetylcholinesterase (AChE) activity.
Rats were divided into five groups: a control, a negative control with only STZ, a standard treatment group with STZ and Rivastigmine, and low- and high-dose sitagliptin groups (5 mg/kg and 10 mg/kg, respectively). Cognitive performance was evaluated using the elevated plus-maze test, which measures spatial memory and anxiety-like behaviors.
It was showed that both low and high doses of sitagliptin led to significant behavioral improvements, with the high dose producing effects comparable to Rivastigmine, the standard AD treatment. Notably, sitagliptin administration reduced AChE activity, correlating with observed cognitive and anxiety-related improvements, suggesting its action may involve modulation of cholinergic pathways. These findings support sitagliptin's potential as an adjunct or alternative treatment for AD, especially considering its dose-dependent effects.
The study underscores the need for further research into sitagliptin’s broader neuroprotective mechanisms, particularly its impact on AD biomarkers such as amyloid-beta and tau proteins. This research provides promising insights into the potential repositioning of sitagliptin for neurodegenerative disease management, highlighting its prospective benefits in AD treatment.
Publié dans World Journal of Pharmaceutical Research. Le résumé est reproduit tel qu’il a été publié et reste l’œuvre de ses auteurs ; lisez l’article complet à la source.
Prognia référence cet article à des fins de documentation et de formation. Il ne constitue pas un avis médical. Lisez toujours l’original et suivez les recommandations en vigueur et les protocoles locaux avant d’agir.
